Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Cantor Fitzgerald
QuintilesIMS
Accenture
Fuji
Express Scripts
Fish and Richardson
Daiichi Sankyo
Novartis
Healthtrust

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,499,757

« Back to Dashboard

Which drugs does patent 8,499,757 protect, and when does it expire?


Patent 8,499,757 protects AFREZZA and is included in one NDA.

This patent has two hundred and thirty-eight patent family members in twenty-three countries.

Summary for Patent: 8,499,757

Title:Dry powder inhaler and system for drug delivery
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Inventor(s): Smutney; Chad C. (Watertown, CT), Kinsey; P. Spencer (Sandy Hook, CT), Sahi; Carl R. (Coventry, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), McLean; Scott (Waterbury, CT), Overfield; Dennis (Fairfield, CT), Bryant; Anthony (Stratford, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:12/484,125
Patent Claim Types:
see list of patent claims
Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,499,757

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,358,352Dry powder drug delivery system and methods► Subscribe
9,283,193Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
8,485,180Dry powder drug delivery system► Subscribe
9,446,001Increasing drug affinity for crystalline microparticle surfaces► Subscribe
9,089,497Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces► Subscribe
8,921,311Method for treating hyperglycemia► Subscribe
7,799,344Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
9,511,198Dry powder inhaler and system for drug delivery► Subscribe
9,717,689Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
8,636,001Dry powder inhaler and system for drug delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,499,757

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2015249177► Subscribe
Australia2015275293► Subscribe
Australia2016200249► Subscribe
BrazilPI0615819► Subscribe
BrazilPI0616071► Subscribe
BrazilPI0709964► Subscribe
BrazilPI0818872► Subscribe
BrazilPI0818874► Subscribe
Canada2493478► Subscribe
China103200940► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Julphar
Federal Trade Commission
McKesson
US Department of Justice
Novartis
Citi
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot